Scipibaimab plus Tislelizumab for advanced nasopharyngeal cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests two drugs—scipibaimab and tislelizumab—given together for people with nasopharyngeal cancer that has not responded to first-line platinum chemotherapy and a PD-1 inhibitor. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your nasopharyngeal cancer has come back or spread to other parts of the body and cannot be cured with surgery or radiation.
- You have tried a platinum-based chemotherapy as your first treatment and it stopped working.
- You have also tried a PD-1 inhibitor (a type of immunotherapy) and it stopped working.
- You are between 18 and 75 years old, and your general health is fairly good (ECOG score 0 or 1).
- You have at least one tumor that can be measured on scans, and your blood counts and organ function are adequate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of chemotherapy and immunotherapy drugs for advanced nasopharyngeal cancer that has not spread to distant parts of the body. The goal is to see if this approach works better than standard treatment.
This trial tests a combination of low-dose radiation and immunotherapy (drugs that help your immune system fight cancer) for people with nasopharyngeal cancer that has spread to other parts of the body and who cannot receive chemotherapy. The goal is to see if this treatment can help control the cancer and improve outcomes.
This study tests whether adding an experimental drug (BL-B01D1) to a standard immunotherapy (anti-PD-1 antibody) as maintenance therapy is better than immunotherapy alone for patients with nasopharyngeal cancer that has spread or come back. The goal is to see if the combination helps keep the cancer from growing longer.
This trial tests a combination of three drugs for people with nasopharyngeal cancer that has come back or spread and stopped responding to first-line chemotherapy. It aims to see if this new combination can help when standard treatment no longer works.
This trial tests a combination of two drugs, becotatug vedotin and sintilimab, for patients with a type of nasopharyngeal cancer that has spread to nearby lymph nodes but not to distant organs. It aims to see if this treatment can help control the disease.
This trial tests a combination of an immunotherapy drug (toripalimab), chemotherapy, radiation, and omega-3 supplements for people with locally advanced nasopharyngeal cancer that hasn't spread. The goal is to see if this approach works better than standard treatment.
Hear when a new Nasopharyngeal Carcinoma (NPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.